Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) EBIT (2024 - 2026)

Updated

Evommune (EVMN) recorded EBIT of -$34.9 million in Q2 2026, compared with -$22.99 million a year earlier.

Analysis

Evommune (EVMN) EBIT (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's EBIT came in at -$101.89 million as of Jun 30, 2026; for FY2025, it was -$81.07 million.

  • Across earlier years, EBIT came in at -$70.01 million in FY2024.
  • The Q2 2026 figure is the lowest quarterly EBIT in data going back to Q3 2024.
  • Per Business Quant, the preceding three quarters came in at -$23.95 million (Q1 2026), -$29.72 million (Q4 2025) and -$13.33 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 7.14 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 6.43 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 3.16 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -10.39 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 4.27 Bn
10 Evommune 186.46 Mn -451.06 Mn - -34.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -34.90 Mn
Mar 31, 2026 -23.95 Mn
Dec 31, 2025 -29.72 Mn
Sep 30, 2025 -13.33 Mn
Jun 30, 2025 -22.99 Mn
Mar 31, 2025 -15.03 Mn
Dec 31, 2024 -21.45 Mn
Sep 30, 2024 -16.52 Mn
API Access

Evommune EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=EVMN&period=max&api_key=YOUR_API_KEY